Executive thought leaders to share strategies for successfully navigating changing regulations and demands in the diagnostics market
SAN DIEGO, Calif. – October 23, 2018 – The laboratory market is continuously changing due to new policies, rules and regulations around reimbursement, coverage and patient data. Labs must continue to rethink their business models and refine their technologies and competitive strategies to be successful in this changing market. At this year’s G2 Intelligence Lab Institute, XIFIN will highlight how the company’s innovation and deep industry expertise helps diagnostic providers address these challenges, meeting both industry requirements and patient expectations. The conference will occur October 24-26, 2018 at the Hyatt Regency Washington on Capitol Hill in Washington D.C.
At booth #106, XIFIN will be showcasing Revenue Performance Management (RPM) 10, the industry’s first machine learning-enabled revenue cycle management (RCM) solution for diagnostic providers. With its next-generation business intelligence visualization and analytics, RPM 10 works to mitigate lost revenue, helping diagnostic providers of all types address the various reimbursement pressures and fee cuts they face due to evolving policies, such as the Protecting Access to Medicare Act (PAMA). In addition, RPM 10 optimizes operations, increases revenue, and fulfills compliance and reporting requirements, while also addressing patient responsibility needs.
“Today’s diagnostics providers are facing an adapt-or-die situation due to increased lab consolidation, compliance requirements and other industry demands,” said Lâle White, CEO, XIFIN. “A recent survey revealed that more than 75% of lab executives anticipate that private payors will institute PAMA-like cuts or that they are already occurring. Tapping into the valuable diagnostic and financial insights that exist within their own businesses will help diagnostic leaders respond to these pressures, driving improved economic and patient outcomes. Without them, however, labs may find it very difficult to thrive.”
Kicking off the conference on the opening night, XIFIN CEO Lâle White will share her insights on PAMA and other challenges that labs are facing due to value-based care initiatives and ongoing reimbursement changes. She will also share the steps labs need to take to address these hurdles and mitigate lost revenue.
Following is a full list of XIFIN executive thought leaders who will be presenting at G2 Intelligence Lab Institute:
Lâle White, Executive Chairman & CEO, XIFIN
- October 24, 2018, 6:00 PM ET: “Master Your Fate: Perspective on the Advantages and Disadvantages Confronting Laboratories in a Post-PAMAgeddon World”
Patricia Goede, VP, Clinical Informatics, XIFIN
- October 24, 2018 (all day): Pre-Conference FutureLab Summit Speaker & Facilitator
- October 25, 2018, 3:50 PM ET: “Medicare Access and CHIP Reauthorization Act (2015) MACRA: What Is It and Why Is It Important?”
Kyle Fetter, EVP & GM of Diagnostic Services, XIFIN
- October 26, 2018, 11:15 AM ET: “The Changing Landscape of Prior Authorizations”
“We are honored to have XIFIN executives once again share their industry expertise with the G2 audience,” said Mark Ziebarth, President and CEO, G2 Intelligence. “XIFIN’s unparalleled experience in the diagnostic industry provides our attendees with the insights and proven best practices they need to navigate the changing healthcare market.”
In its 36th year, the G2 Intelligence Annual Lab Institute hosts laboratory and diagnostic leaders from across the healthcare industry to discuss market trends, legal and regulatory developments, and technology and innovation that directly affect the operations, financial performance, and competitive position of diagnostic testing laboratories and related medical services providers. For more information about the upcoming conference and to view the full conference agenda, visit here.